Other innovative partnerships

We are very committed to fuel our pipeline with innovative targeted therapies in high unmet medical needs in life-threatening diseases.


Global agreement for a class I PI3K inhibitor, granting Menarini Group an exclusive license for the manufacturing, development and marketing of the product worldwide, thus adding a key component in the R&D portfolio.

 Strategic partnership, covering the development and commercialization of OBT's proprietary antibody-based cancer therapies. Menarini is responsible for the manufacture and clinical development of each program up to clinical proof of concept. OBT retains the rights to develop and commercialize in some territories, most notably North America and Japan.The agreement represented the first step in building the Menarini pipeline in biologics.


The agreement granted Menarini Group the rights to research, develop, manufacture and commercialize worldwide a dual first-in-class orally available PIM/FLT3 inhibitor, in Phase I/II trials in acute myeloid leukemia patients, allowing the entrance of Menarini in the fight against this life-threatening disease.


InSilico granted Stemline Inc a worldwide exclusive license to develop and commercialize a novel, small molecule KAT6A inhibitor designed using Insilico’s AI platform, as a potential treatment for hormone sensitive cancers and other oncology indications.